Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile PIK3CA wild-type
Therapy Lapatinib + Paclitaxel + Trastuzumab
Indication/Tumor Type Her2-receptor positive breast cancer
Response Type sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
PIK3CA wild-type Her2-receptor positive breast cancer sensitive Lapatinib + Paclitaxel + Trastuzumab Phase II Actionable In a Phase II trial, the combination of Taxol (paclitaxel) plus Herceptin (trastuzumab) and Tykerb (lapatinib) resulted in a higher pathologic complete remission rate in ERBB2 (HER2)-receptor positive breast cancer patients with PIK3CA wild-type compared to those harboring a PIK3CA mutation (PMID: 26245675). 26245675
PubMed Id Reference Title Details
(26245675) Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer. Full reference...